Skip to content

Discrepancies between publication, protocol and registration

Ioana A. Cristea, Florian Naudet, Clara Miguel

May 12, 2021 preprint DOI: 10.31219/osf.io/ne26f (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Letter to the editor
Keywords Protocol science Information retrieval
Citations 1
Key points The letter argues that the trial's comparison of psilocybin to escitalopram may be biased by inadequate blinding and expectancy effects, questioning the validity of the reported superiority of psilocybin.

Abstract

Letter to the editor in reference to Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. The New England journal of medicine 2021;384:1402-11.

Related reading

Explore topics

Depression Psilocybin